Advanced International Journal for Research

E-ISSN: 3048-7641   •   Impact Factor: 9.11

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 1 (January-February 2026) Submit your research before last 3 days of February to publish your research paper in the issue of January-February.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 1
January-February 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Beyond the Monopoly: the Role of Open Source Drug Discovery Models in Nurturing Equitable Access to Medicines

Author(s) Dr. KUMARA N H
Country India
Abstract This paper explores the capability of open-source drug discovery models as an alternative to the traditional, patent-based system for nurturing equitable access to medicines. The conventional model, while a driver of innovation, often leads to market failures, such as the neglect of diseases prevalent in low-income countries and the creation of price-based barriers to access. Open -source drug discovery, inspired by the open-source software movement, proposes a fundamentally different approach: all the research data, compounds, and findings are made freely and publicly available, thereby creating a collaborative ‘common’ of knowledge.
The core argument of this research is that, this alternative model can effectively decouple innovation from the profit motive, leading to a more equitable distribution of scientific progress. To illustrate its viability, the paper presents a case study of the ‘Structural Genomics Consortium’ (SGC), a leading open-access research organization that has demonstrated the power of a non-proprietary approach to drug discovery. The SGC’s success in rapidly generating and sharing protein structures has accelerated research across the globe, showcasing a new pathway for biomedical science. This paper concludes by summarizing the model’s key strengths, including its ability to address neglected diseases and lower R & D costs, and offers policy recommendations for its wider adoption, such as public funding and the creation of collaborative legal frameworks.
Keywords Open Source Drug Discovery (OSDD), Patents, Equitable Access to Medicines, Intellectual Property Rights (IPR), Structural Genomics Consortium (SGC), Public Health, R & D, Collaborative Research, Public Private Partnerships (PPPs).
Field Sociology > Administration / Law / Management
Published In Volume 7, Issue 1, January-February 2026
Published On 2026-01-24
DOI https://doi.org/10.63363/aijfr.2026.v07i01.3018
Short DOI https://doi.org/hbmz2v
View / Download PDF File

Share this



E-ISSN 3048-7641
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

AIJFR DOI prefix is
10.63363/aijfr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 1Cover Page Vol 6 Isu 6Cover Page Vol 6 Isu 5

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About AIJFR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-79-39-59 editor@aijfr.com